These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 9351880)

  • 1. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates.
    Thiébaud D; Sauty A; Burckhardt P; Leuenberger P; Sitzler L; Green JR; Kandra A; Zieschang J; Ibarra de Palacios P
    Calcif Tissue Int; 1997 Nov; 61(5):386-92. PubMed ID: 9351880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy.
    Sauty A; Pecherstorfer M; Zimmer-Roth I; Fioroni P; Juillerat L; Markert M; Ludwig H; Leuenberger P; Burckhardt P; Thiebaud D
    Bone; 1996 Feb; 18(2):133-9. PubMed ID: 8833207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6.
    Dicuonzo G; Vincenzi B; Santini D; Avvisati G; Rocci L; Battistoni F; Gavasci M; Borzomati D; Coppola R; Tonini G
    J Interferon Cytokine Res; 2003 Nov; 23(11):649-54. PubMed ID: 14651779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute effects of intravenous administration of pamidronate in patients with osteoporosis.
    Lim MJ; Kwon SR; Park SG; Park W
    J Korean Med Sci; 2010 Sep; 25(9):1277-83. PubMed ID: 20808669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Injectable bisphosphonates in the treatment of postmenopausal osteoporosis.
    Sartori L; Adami S; Filipponi P; Crepaldi G
    Aging Clin Exp Res; 2003 Aug; 15(4):271-83. PubMed ID: 14661816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro.
    Pennanen N; Lapinjoki S; Urtti A; Mönkkönen J
    Pharm Res; 1995 Jun; 12(6):916-22. PubMed ID: 7667201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease.
    Fiotti N; Giansante C; Ponte E; Delbello C; Calabrese S; Zacchi T; Dobrina A; Guarnieri G
    Atherosclerosis; 1999 Jul; 145(1):51-60. PubMed ID: 10428295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.
    Merlotti D; Gennari L; Martini G; Valleggi F; De Paola V; Avanzati A; Nuti R
    J Bone Miner Res; 2007 Oct; 22(10):1510-7. PubMed ID: 17605632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women.
    Thompson K; Keech F; McLernon DJ; Vinod K; May RJ; Simpson WG; Rogers MJ; Reid DM
    Bone; 2011 Jul; 49(1):140-5. PubMed ID: 21047568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukins and their antagonists but not TNF and its receptors are released in post-ERP pancreatitis.
    Messmann H; Vogt W; Falk W; Vogl D; Zirngibl H; Leser HG; Schölmerich J
    Eur J Gastroenterol Hepatol; 1998 Jul; 10(7):611-7. PubMed ID: 9855088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient changes in thyroid functions tests after zoledronic acid infusion.
    Karga H; Giagourta I; Papaioannou G; Katsichti P; Pardalakis A; Kassi G; Zagoreou A; Triantaphyllopoulou M; Zerva C
    Endocr J; 2011; 58(11):969-77. PubMed ID: 21891972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current management strategies for hypercalcemia.
    Pecherstorfer M; Brenner K; Zojer N
    Treat Endocrinol; 2003; 2(4):273-92. PubMed ID: 15966562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
    Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE
    Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.
    Terpos E; Morgan G; Dimopoulos MA; Drake MT; Lentzsch S; Raje N; Sezer O; García-Sanz R; Shimizu K; Turesson I; Reiman T; Jurczyszyn A; Merlini G; Spencer A; Leleu X; Cavo M; Munshi N; Rajkumar SV; Durie BG; Roodman GD
    J Clin Oncol; 2013 Jun; 31(18):2347-57. PubMed ID: 23690408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of oral clodronate compared with oral ibandronate, intravenous zoledronate or intravenous pamidronate in breast cancer patients.
    Paterson A; McCloskey E; Redzepovic J; Ott I; Gust R
    J Int Med Res; 2008; 36(3):400-13. PubMed ID: 18534121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.
    Berenson JR; Hillner BE; Kyle RA; Anderson K; Lipton A; Yee GC; Biermann JS;
    J Clin Oncol; 2002 Sep; 20(17):3719-36. PubMed ID: 12202673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass.
    Anastasilakis AD; Polyzos SA; Makras P; Sakellariou GT; Bisbinas I; Gkiomisi A; Delaroudis S; Gerou S; Ballaouri I; Oikonomou D; Papapoulos SE
    Bone; 2012 May; 50(5):1130-4. PubMed ID: 22366634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased tumor necrosis factor alpha (TNF alpha), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates: relationship between TNF alpha and IL-6 levels and febrile transfusion reactions.
    Muylle L; Joos M; Wouters E; De Bock R; Peetermans ME
    Transfusion; 1993 Mar; 33(3):195-9. PubMed ID: 8438219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.